text: Deutetrabenazine is a deuterated version of tetrabenazine. It was developed by Auspex then acquired by Teva in 2015 and approved by the FDA in 2017 as a treatment for chorea associated with Huntington's disease; it has a longer half life than the non-deuterated form of tetrabenazine, which had been approved earlier for the same use.
  Deucravacitinib is a deuterated JAK inhibitor (specifically, TYK2 inhibitor) approved for the treatment of plaque psoriasis.
  Concert Pharmaceuticals focuses on deuterated drugs for various conditions. Concert was acquired by Sun Pharma in March 2023.
  The company Retrotope discovered and has been developing a deuterated fatty acid RT001 as a treatment for neurodegenerative diseases such as Friedreich's ataxia and infantile neuroaxonal dystrophy. Their premise is that fatty acids in cell membranes are a source of reactive oxygen species and deuterated versions will be less prone to generating them.
  Poxel SA, a French clinical-stage biopharmaceutical company focused on therapies for rare metabolic diseases, is developing PXL065 to target non-alcoholic steatohepatitis (NASH). The company acquired PXL065 (the deuterium-stabilized (R)-enantiomer of pioglitazone) and a portfolio of deuterated thiazolidinediones (TZDs) from DeuteRx, LLC, in 2018, and published positive results from the Phase 2 trial in March 2023.